Emerging evidence supports the skin microbiome as a promising avenue for precision medicine in the treatment of dermatologic ...

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune ...

If your current eczema routine only offers temporary relief, it may be time for a change. Learn how to address underlying inflammation and find a treatment that fits your busy lifestyle.

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis (AD), also known as eczema. Data from the REZOLVE-AD study of ...

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in ...

Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 2:30 PM ESTCompany ParticipantsRafael Amado - President and Head ...

The FDA has approved topical difamilast for treating mild-to-moderate atopic dermatitis (AD) in adults and children aged 2 years or older, according to a press release from the manufacturer, Acrotech ...

Achieve near-complete or complete skin clearance, as reflected by a Validated Investigator Global Assessment score of clear (vIGA-AD 0, 36.4% vs 0%, p=0.006) Report higher rates of “no itch” (45.5% vs ...

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a ...

A staged approach for a patient decision aid can help to deliver complex information and facilitate shared decision-making in adults with atopic dermatitis.

Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc.